CONTEXT: Participants in a randomized trial of traditional Chinese medicine (TCM) for temporomandibular joint dysfunction (TMD) had a linear decline in pain over 16 TCM visits. OBJECTIVE: To investigate whether reductions in pain among participants receiving TCM can be explained by increased use of pain medications, or whether use of pain medications also declined in this group. DESIGN: One hundred sixty-eight participants with TMD were treated with TCM or enhanced self-care according to a stepped-care design. Those for whom self-care failed were sequentially randomized to further self-care or TCM. This report includes 111 participants during their first 16 TCM visits. The initial 8 visits occurred more than once a week; participants and practitioners determined the frequency of subsequent visits. OUTCOME MEASURES: Average pain (visual analog scale, range 0-10) and morphine and aspirin dose equivalents. RESULTS: The sample was 87% women and the average age was 44 ± 13 years. Average pain of narcotics users (n = 21) improved by 2.73 units over 16 visits (p < 0.001). Overall narcotics use trended downward until visit 11 (-3.27 doses/week, p = 0.156), and then trended upward until week 16 (+4.29 doses/week, p = 0.264). Among those using narcotics, use of nonsteroidal anti-inflammatory drugs (NSAIDs) declined linearly over visits 1-16 (-1.94 doses/week, p = 0.002).Among the top quartile of NSAID-only users (n = 22), average pain decreased linearly over 16 visits (-1.52 units, p = 0.036). Overall NSAID doses/week declined between visits 1 and 7 (-9.95 doses/week, p < 0.001) and then remained stable through 16 visits. NSAID use also declined among the third quartile (n = 23) and remained low and stable among the lower half (sorted by total intake) of NSAID users. CONCLUSIONS: Among the heaviest NSAID users, we observed a short-term reduction in NSAID use that was sustained as TCM visits became less frequent. There was no indication that pain reduction during TCM treatment was influenced by drug use.
CONTEXT: Participants in a randomized trial of traditional Chinese medicine (TCM) for temporomandibular joint dysfunction (TMD) had a linear decline in pain over 16 TCM visits. OBJECTIVE: To investigate whether reductions in pain among participants receiving TCM can be explained by increased use of pain medications, or whether use of pain medications also declined in this group. DESIGN: One hundred sixty-eight participants with TMD were treated with TCM or enhanced self-care according to a stepped-care design. Those for whom self-care failed were sequentially randomized to further self-care or TCM. This report includes 111 participants during their first 16 TCM visits. The initial 8 visits occurred more than once a week; participants and practitioners determined the frequency of subsequent visits. OUTCOME MEASURES: Average pain (visual analog scale, range 0-10) and morphine and aspirin dose equivalents. RESULTS: The sample was 87% women and the average age was 44 ± 13 years. Average pain of narcotics users (n = 21) improved by 2.73 units over 16 visits (p < 0.001). Overall narcotics use trended downward until visit 11 (-3.27 doses/week, p = 0.156), and then trended upward until week 16 (+4.29 doses/week, p = 0.264). Among those using narcotics, use of nonsteroidal anti-inflammatory drugs (NSAIDs) declined linearly over visits 1-16 (-1.94 doses/week, p = 0.002).Among the top quartile of NSAID-only users (n = 22), average pain decreased linearly over 16 visits (-1.52 units, p = 0.036). Overall NSAID doses/week declined between visits 1 and 7 (-9.95 doses/week, p < 0.001) and then remained stable through 16 visits. NSAID use also declined among the third quartile (n = 23) and remained low and stable among the lower half (sorted by total intake) of NSAID users. CONCLUSIONS: Among the heaviest NSAID users, we observed a short-term reduction in NSAID use that was sustained as TCM visits became less frequent. There was no indication that pain reduction during TCM treatment was influenced by drug use.
Authors: Cheryl Ritenbaugh; Marja Verhoef; Susan Fleishman; Heather Boon; Ann Leis Journal: Altern Ther Health Med Date: 2003 Jul-Aug Impact factor: 1.305
Authors: Charles Elder; Mikel Aickin; Iris R Bell; Vinjar Fønnebø; George T Lewith; Cheryl Ritenbaugh; Marja Verhoef Journal: J Altern Complement Med Date: 2006-11 Impact factor: 2.579
Authors: Claudia M Witt; Susanne Jena; Dagmar Selim; Benno Brinkhaus; Thomas Reinhold; Katja Wruck; Bodo Liecker; Klaus Linde; Karl Wegscheider; Stefan N Willich Journal: Am J Epidemiol Date: 2006-06-23 Impact factor: 4.897
Authors: Cheryl Ritenbaugh; Richard Hammerschlag; Carlo Calabrese; Scott Mist; Mikel Aickin; Elizabeth Sutherland; Joseph Leben; Lynn Debar; Charles Elder; Samuel F Dworkin Journal: J Altern Complement Med Date: 2008-06 Impact factor: 2.579
Authors: Cheryl Ritenbaugh; Richard Hammerschlag; Samuel F Dworkin; Mikel G Aickin; Scott D Mist; Charles R Elder; Richard E Harris Journal: J Pain Date: 2012-10-09 Impact factor: 5.820
Authors: Chenfang Liu; Yuehui Zhang; Sai Kong; Ilene Tsui; Yang Yu; Fengjuan Han Journal: Evid Based Complement Alternat Med Date: 2014-02-04 Impact factor: 2.629
Authors: Claudia M Witt; Mikel Aickin; Daniel Cherkin; Chun Tao Che; Charles Elder; Andrew Flower; Richard Hammerschlag; Jian-Ping Liu; Lixing Lao; Steve Phurrough; Cheryl Ritenbaugh; Lee Hullender Rubin; Rosa Schnyer; Peter M Wayne; Shelly Rafferty Withers; Bian Zhao-Xiang; Jeanette Young; Brian M Berman Journal: Trials Date: 2014-05-13 Impact factor: 2.279